NCT05065983View on ClinicalTrials.gov

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine

PHASE2CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

May 5, 2022

Study Completion Date

May 5, 2022

Conditions

Chikungunya Virus

Interventions

BIOLOGICAL

CHIKV VLP, adjuvanted

Adjuvanted formulation includes aluminum hydroxide

Trial Locations (1)

66219

Johnson County ClinTrials, Lenexa

Sponsors

Lead Sponsor

Bavarian Nordic

Collaborators (1)

Emergent BioSolutions

All Listed Sponsors

collaborator

Emergent BioSolutions

INDUSTRY

lead

Bavarian Nordic

INDUSTRY